In the present study, we report our findings that support an additional shared pathway underlying the detrimental effects of TDP-43 and FUS aggregation in the cytoplasm, and explore a potential therapeutic avenue for the treatment of neurodegenerative diseases with TDP-43 and FUS proteinopathies. This evidence concerns the gene TARDBP and proteostasis deficiencies.